ANDA Backlog: FDA Climbs The Mountain, Will Need To Climb It Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency has acted on 84% of generic applications pending when user fee program launched, but most actions were 'complete response' letters, which do not reduce review workload.
You may also be interested in...
First Generic Approvals Decline For Fourth Straight Year At US FDA
Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.
First Generic Approvals Decline For Fourth Straight Year At US FDA
Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.
ANDA Withdrawals Increase Faster Than Approvals
FY 2016 figure, the highest seen by US FDA under the generic drug user fee program, could be the result of older applications exiting the queue, and may be a sign of progress in dealing with the review backlog.